Cargando…

The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial

BACKGROUND: Sodium bicarbonate (SB) has been proposed as an ergogenic aid, as it improves high-intensity and resistance exercise performance. However, no studies have yet investigated SB application in CrossFit. This study examined the effects of chronic, progressive-dose SB ingestion on CrossFit-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Durkalec-Michalski, Krzysztof, Zawieja, Emilia E., Podgórski, Tomasz, Łoniewski, Igor, Zawieja, Bogna E., Warzybok, Marta, Jeszka, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957406/
https://www.ncbi.nlm.nih.gov/pubmed/29771966
http://dx.doi.org/10.1371/journal.pone.0197480
_version_ 1783324058376470528
author Durkalec-Michalski, Krzysztof
Zawieja, Emilia E.
Podgórski, Tomasz
Łoniewski, Igor
Zawieja, Bogna E.
Warzybok, Marta
Jeszka, Jan
author_facet Durkalec-Michalski, Krzysztof
Zawieja, Emilia E.
Podgórski, Tomasz
Łoniewski, Igor
Zawieja, Bogna E.
Warzybok, Marta
Jeszka, Jan
author_sort Durkalec-Michalski, Krzysztof
collection PubMed
description BACKGROUND: Sodium bicarbonate (SB) has been proposed as an ergogenic aid, as it improves high-intensity and resistance exercise performance. However, no studies have yet investigated SB application in CrossFit. This study examined the effects of chronic, progressive-dose SB ingestion on CrossFit-like performance and aerobic capacity. METHODS: In a randomized, double-blind, cross-over trial, 21 CrossFit-trained participants were randomly allocated to 2 groups and underwent 2 trials separated by a 14-day washout period. Participants ingested either up to 150 mg∙kg(-1) of SB in a progressive-dose regimen or placebo for 10 days. Before and after each trial, Fight Gone Bad (FGB) and incremental cycling (ICT) tests were performed. In order to examine biochemical responses, blood samples were obtained prior to and 3 min after completing each exercise test. RESULTS: No gastrointestinal (GI) side effects were reported during the entire protocol. The overall FGB performance improved under SB by ~6.1% (p<0.001) and it was ~3.1% higher compared to post placebo (PLA(post)) (p = 0.040). The number of repetitions completed in each round also improved under SB (mean from baseline: +5.8% to +6.4%). Moreover, in ICT, the time to ventilatory threshold (VT) (~8:25 min SB(post) vs. ~8:00 min PLA(post), p = 0.020), workload at VT (~218 W SB(post) vs. ~208 W PLA(post), p = 0.037) and heart rate at VT (~165 bpm SB(post) vs. ~161 bpm PLA(post), p = 0.030) showed higher SB(post) than PLA(post). Furthermore, the maximum carbon dioxide production increased under SB by ~4.8% (from ~3604 mL∙min(-1) to ~3776 mL∙min(-1), p = 0.049). Pyruvate concentration and creatine kinase activity before ICT showed higher SB(post) than PLA(post) (~0.32 mmol∙L(-1) vs. ~0.26 mmol∙L(-1), p = 0.001; ~275 U∙L(-1) vs. ~250 U∙L(-1), p = 0.010, respectively). However, the small sample size limits the wide-application of our results. CONCLUSIONS: Progressive-dose SB ingestion regimen eliminated GI side effects and improved CrossFit-like performance, as well as delayed ventilatory threshold occurrence.
format Online
Article
Text
id pubmed-5957406
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59574062018-05-31 The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial Durkalec-Michalski, Krzysztof Zawieja, Emilia E. Podgórski, Tomasz Łoniewski, Igor Zawieja, Bogna E. Warzybok, Marta Jeszka, Jan PLoS One Research Article BACKGROUND: Sodium bicarbonate (SB) has been proposed as an ergogenic aid, as it improves high-intensity and resistance exercise performance. However, no studies have yet investigated SB application in CrossFit. This study examined the effects of chronic, progressive-dose SB ingestion on CrossFit-like performance and aerobic capacity. METHODS: In a randomized, double-blind, cross-over trial, 21 CrossFit-trained participants were randomly allocated to 2 groups and underwent 2 trials separated by a 14-day washout period. Participants ingested either up to 150 mg∙kg(-1) of SB in a progressive-dose regimen or placebo for 10 days. Before and after each trial, Fight Gone Bad (FGB) and incremental cycling (ICT) tests were performed. In order to examine biochemical responses, blood samples were obtained prior to and 3 min after completing each exercise test. RESULTS: No gastrointestinal (GI) side effects were reported during the entire protocol. The overall FGB performance improved under SB by ~6.1% (p<0.001) and it was ~3.1% higher compared to post placebo (PLA(post)) (p = 0.040). The number of repetitions completed in each round also improved under SB (mean from baseline: +5.8% to +6.4%). Moreover, in ICT, the time to ventilatory threshold (VT) (~8:25 min SB(post) vs. ~8:00 min PLA(post), p = 0.020), workload at VT (~218 W SB(post) vs. ~208 W PLA(post), p = 0.037) and heart rate at VT (~165 bpm SB(post) vs. ~161 bpm PLA(post), p = 0.030) showed higher SB(post) than PLA(post). Furthermore, the maximum carbon dioxide production increased under SB by ~4.8% (from ~3604 mL∙min(-1) to ~3776 mL∙min(-1), p = 0.049). Pyruvate concentration and creatine kinase activity before ICT showed higher SB(post) than PLA(post) (~0.32 mmol∙L(-1) vs. ~0.26 mmol∙L(-1), p = 0.001; ~275 U∙L(-1) vs. ~250 U∙L(-1), p = 0.010, respectively). However, the small sample size limits the wide-application of our results. CONCLUSIONS: Progressive-dose SB ingestion regimen eliminated GI side effects and improved CrossFit-like performance, as well as delayed ventilatory threshold occurrence. Public Library of Science 2018-05-17 /pmc/articles/PMC5957406/ /pubmed/29771966 http://dx.doi.org/10.1371/journal.pone.0197480 Text en © 2018 Durkalec-Michalski et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Durkalec-Michalski, Krzysztof
Zawieja, Emilia E.
Podgórski, Tomasz
Łoniewski, Igor
Zawieja, Bogna E.
Warzybok, Marta
Jeszka, Jan
The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial
title The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial
title_full The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial
title_fullStr The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial
title_full_unstemmed The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial
title_short The effect of chronic progressive-dose sodium bicarbonate ingestion on CrossFit-like performance: A double-blind, randomized cross-over trial
title_sort effect of chronic progressive-dose sodium bicarbonate ingestion on crossfit-like performance: a double-blind, randomized cross-over trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957406/
https://www.ncbi.nlm.nih.gov/pubmed/29771966
http://dx.doi.org/10.1371/journal.pone.0197480
work_keys_str_mv AT durkalecmichalskikrzysztof theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT zawiejaemiliae theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT podgorskitomasz theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT łoniewskiigor theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT zawiejabognae theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT warzybokmarta theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT jeszkajan theeffectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT durkalecmichalskikrzysztof effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT zawiejaemiliae effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT podgorskitomasz effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT łoniewskiigor effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT zawiejabognae effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT warzybokmarta effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial
AT jeszkajan effectofchronicprogressivedosesodiumbicarbonateingestiononcrossfitlikeperformanceadoubleblindrandomizedcrossovertrial